Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 39 | 2023 | 312 | 8.010 |
Why?
|
| Endometrial Neoplasms | 16 | 2023 | 66 | 4.870 |
Why?
|
| Neoplasms, Glandular and Epithelial | 10 | 2017 | 40 | 2.430 |
Why?
|
| Diet | 10 | 2022 | 801 | 1.820 |
Why?
|
| Prospective Studies | 42 | 2024 | 1378 | 1.690 |
Why?
|
| Cohort Studies | 29 | 2024 | 1492 | 1.590 |
Why?
|
| Middle Aged | 61 | 2024 | 10129 | 1.430 |
Why?
|
| Breast Neoplasms | 16 | 2024 | 1502 | 1.410 |
Why?
|
| Risk Factors | 45 | 2024 | 3562 | 1.390 |
Why?
|
| Receptors, Progesterone | 8 | 2021 | 81 | 1.340 |
Why?
|
| Female | 78 | 2024 | 20969 | 1.330 |
Why?
|
| Gonadal Steroid Hormones | 5 | 2021 | 51 | 1.170 |
Why?
|
| Insulin | 2 | 2021 | 236 | 1.140 |
Why?
|
| Case-Control Studies | 30 | 2022 | 1130 | 1.130 |
Why?
|
| Receptors, Estrogen | 7 | 2021 | 156 | 1.090 |
Why?
|
| Postmenopause | 5 | 2021 | 128 | 1.080 |
Why?
|
| Dietary Fats | 3 | 2015 | 119 | 1.080 |
Why?
|
| Aged | 35 | 2024 | 6741 | 1.040 |
Why?
|
| Humans | 82 | 2024 | 37093 | 1.010 |
Why?
|
| Dairy Products | 2 | 2014 | 35 | 0.900 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 121 | 0.880 |
Why?
|
| Parity | 10 | 2024 | 46 | 0.880 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 626 | 0.860 |
Why?
|
| Adult | 42 | 2024 | 11712 | 0.840 |
Why?
|
| Parabens | 1 | 2021 | 7 | 0.790 |
Why?
|
| Phthalic Acids | 1 | 2021 | 13 | 0.780 |
Why?
|
| Europe | 19 | 2022 | 101 | 0.780 |
Why?
|
| Analgesics | 2 | 2018 | 54 | 0.780 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 251 | 0.780 |
Why?
|
| Somatomedins | 1 | 2021 | 5 | 0.780 |
Why?
|
| Body Weights and Measures | 1 | 2021 | 22 | 0.780 |
Why?
|
| Gonadal Hormones | 1 | 2021 | 6 | 0.770 |
Why?
|
| Prognosis | 16 | 2021 | 739 | 0.770 |
Why?
|
| Follow-Up Studies | 17 | 2021 | 974 | 0.770 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 43 | 0.760 |
Why?
|
| Phenols | 1 | 2021 | 80 | 0.730 |
Why?
|
| Cystadenocarcinoma, Serous | 7 | 2019 | 35 | 0.730 |
Why?
|
| Aspirin | 2 | 2018 | 49 | 0.700 |
Why?
|
| Nutritional Status | 4 | 2021 | 116 | 0.690 |
Why?
|
| Fatty Acids | 2 | 2020 | 127 | 0.670 |
Why?
|
| State Medicine | 1 | 2018 | 5 | 0.660 |
Why?
|
| Acetaminophen | 1 | 2018 | 27 | 0.640 |
Why?
|
| Ovary | 3 | 2019 | 108 | 0.630 |
Why?
|
| Proportional Hazards Models | 11 | 2024 | 441 | 0.590 |
Why?
|
| Reproductive History | 6 | 2024 | 19 | 0.590 |
Why?
|
| Feeding Behavior | 3 | 2015 | 454 | 0.580 |
Why?
|
| Menarche | 4 | 2024 | 13 | 0.540 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 44 | 0.530 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2017 | 70 | 0.530 |
Why?
|
| Endometrium | 1 | 2016 | 60 | 0.520 |
Why?
|
| Life Style | 4 | 2024 | 308 | 0.510 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2014 | 9 | 0.490 |
Why?
|
| Premenopause | 8 | 2018 | 104 | 0.490 |
Why?
|
| Risk | 8 | 2019 | 267 | 0.480 |
Why?
|
| Menopause | 8 | 2024 | 56 | 0.470 |
Why?
|
| Fallopian Tubes | 1 | 2013 | 17 | 0.470 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 358 | 0.450 |
Why?
|
| Age Factors | 6 | 2024 | 1033 | 0.440 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2017 | 16 | 0.430 |
Why?
|
| Adenocarcinoma, Clear Cell | 5 | 2017 | 15 | 0.430 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2012 | 2 | 0.430 |
Why?
|
| Talc | 2 | 2013 | 3 | 0.430 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1207 | 0.410 |
Why?
|
| Risk Assessment | 5 | 2018 | 753 | 0.410 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 275 | 0.400 |
Why?
|
| Acrylamide | 3 | 2015 | 7 | 0.390 |
Why?
|
| Incidence | 9 | 2024 | 922 | 0.390 |
Why?
|
| Body Mass Index | 6 | 2022 | 854 | 0.390 |
Why?
|
| Food | 1 | 2012 | 100 | 0.390 |
Why?
|
| Contraceptives, Oral | 3 | 2015 | 14 | 0.380 |
Why?
|
| Pregnancy | 11 | 2024 | 1549 | 0.380 |
Why?
|
| Early Detection of Cancer | 4 | 2018 | 336 | 0.370 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 485 | 0.370 |
Why?
|
| Epithelial Cells | 1 | 2013 | 384 | 0.370 |
Why?
|
| Vitamin D | 1 | 2012 | 196 | 0.350 |
Why?
|
| CA-125 Antigen | 3 | 2018 | 9 | 0.350 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2017 | 4 | 0.340 |
Why?
|
| Iron, Dietary | 2 | 2018 | 13 | 0.330 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 172 | 0.320 |
Why?
|
| Heme | 2 | 2018 | 70 | 0.310 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2008 | 19 | 0.310 |
Why?
|
| Breast Feeding | 4 | 2018 | 113 | 0.310 |
Why?
|
| United States | 7 | 2023 | 4223 | 0.300 |
Why?
|
| Osteoprotegerin | 2 | 2017 | 10 | 0.300 |
Why?
|
| Autoantibodies | 2 | 2018 | 103 | 0.290 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2017 | 23 | 0.280 |
Why?
|
| Carcinoma | 2 | 2019 | 96 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 628 | 0.270 |
Why?
|
| Epoxy Compounds | 2 | 2015 | 15 | 0.270 |
Why?
|
| Nutrition Assessment | 4 | 2020 | 79 | 0.260 |
Why?
|
| Hemoglobins | 2 | 2015 | 107 | 0.260 |
Why?
|
| Androgens | 2 | 2017 | 89 | 0.260 |
Why?
|
| Sex Hormone-Binding Globulin | 4 | 2017 | 20 | 0.250 |
Why?
|
| Young Adult | 8 | 2021 | 4268 | 0.240 |
Why?
|
| Gallbladder Neoplasms | 1 | 2024 | 2 | 0.240 |
Why?
|
| Estrogen Receptor alpha | 2 | 2016 | 111 | 0.240 |
Why?
|
| Contraceptives, Oral, Hormonal | 4 | 2017 | 13 | 0.230 |
Why?
|
| Inflammation | 4 | 2021 | 618 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 88 | 0.210 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 149 | 0.210 |
Why?
|
| Vitamin A | 1 | 2022 | 87 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 251 | 0.200 |
Why?
|
| Netherlands | 2 | 2022 | 10 | 0.190 |
Why?
|
| Asia | 4 | 2024 | 75 | 0.190 |
Why?
|
| Leptin | 1 | 2022 | 118 | 0.190 |
Why?
|
| Odds Ratio | 4 | 2019 | 534 | 0.180 |
Why?
|
| Adiposity | 1 | 2021 | 154 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 128 | 0.180 |
Why?
|
| Stromal Cells | 1 | 2019 | 49 | 0.180 |
Why?
|
| Neoplasms | 3 | 2017 | 1103 | 0.170 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 333 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 583 | 0.170 |
Why?
|
| Parturition | 1 | 2018 | 24 | 0.170 |
Why?
|
| Prolactin | 2 | 2017 | 62 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 494 | 0.160 |
Why?
|
| Disease Progression | 1 | 2021 | 601 | 0.160 |
Why?
|
| Meat | 1 | 2018 | 43 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2017 | 238 | 0.160 |
Why?
|
| Retrospective Studies | 1 | 2023 | 2026 | 0.150 |
Why?
|
| Genotype | 3 | 2018 | 730 | 0.150 |
Why?
|
| Glioma | 1 | 2018 | 79 | 0.150 |
Why?
|
| RANK Ligand | 1 | 2017 | 13 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 213 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 59 | 0.150 |
Why?
|
| Survival Rate | 2 | 2015 | 311 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 306 | 0.150 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 2379 | 0.150 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 23 | 0.140 |
Why?
|
| Genetic Loci | 1 | 2017 | 90 | 0.140 |
Why?
|
| Adolescent | 5 | 2024 | 5363 | 0.140 |
Why?
|
| Body Height | 1 | 2017 | 53 | 0.140 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2016 | 4 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 3 | 0.140 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2016 | 23 | 0.140 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 26 | 0.140 |
Why?
|
| Receptor, Insulin | 1 | 2016 | 25 | 0.140 |
Why?
|
| New England | 2 | 2013 | 16 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 54 | 0.130 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2016 | 39 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 893 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2010 | 807 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 441 | 0.130 |
Why?
|
| Coronary Disease | 1 | 2016 | 124 | 0.130 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 12 | 0.130 |
Why?
|
| Epidemiologic Studies | 1 | 2015 | 31 | 0.130 |
Why?
|
| Phosphoproteins | 1 | 2016 | 163 | 0.130 |
Why?
|
| Diet Records | 1 | 2015 | 60 | 0.120 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2014 | 3 | 0.120 |
Why?
|
| Male | 7 | 2021 | 20025 | 0.120 |
Why?
|
| Estrogens | 1 | 2016 | 202 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2014 | 16 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 178 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2017 | 517 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 123 | 0.120 |
Why?
|
| Cell Line, Transformed | 1 | 2013 | 91 | 0.120 |
Why?
|
| Powders | 1 | 2013 | 17 | 0.110 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2016 | 18 | 0.110 |
Why?
|
| Logistic Models | 2 | 2015 | 923 | 0.110 |
Why?
|
| Hysterectomy | 1 | 2013 | 28 | 0.110 |
Why?
|
| Gene Expression | 1 | 2016 | 674 | 0.110 |
Why?
|
| Lactose | 1 | 2012 | 14 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 562 | 0.110 |
Why?
|
| Nurses | 1 | 2013 | 48 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 277 | 0.100 |
Why?
|
| Calcium, Dietary | 1 | 2012 | 85 | 0.100 |
Why?
|
| Spheroids, Cellular | 1 | 2011 | 28 | 0.100 |
Why?
|
| Epithelium | 1 | 2011 | 79 | 0.100 |
Why?
|
| Hormones | 2 | 2024 | 55 | 0.090 |
Why?
|
| Australia | 2 | 2008 | 76 | 0.090 |
Why?
|
| China | 2 | 2024 | 196 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 664 | 0.090 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2231 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 1371 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2019 | 325 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2017 | 88 | 0.070 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 50 | 0.070 |
Why?
|
| ROC Curve | 2 | 2017 | 138 | 0.070 |
Why?
|
| Maternal Age | 2 | 2018 | 26 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 2721 | 0.070 |
Why?
|
| Animals | 3 | 2013 | 15081 | 0.070 |
Why?
|
| Phenotype | 2 | 2021 | 689 | 0.070 |
Why?
|
| Animal Migration | 1 | 2005 | 3 | 0.070 |
Why?
|
| Moths | 1 | 2005 | 10 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 2 | 2017 | 30 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2008 | 484 | 0.060 |
Why?
|
| Testosterone | 2 | 2017 | 193 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 448 | 0.060 |
Why?
|
| Republic of Korea | 1 | 2024 | 107 | 0.060 |
Why?
|
| Work Schedule Tolerance | 1 | 2023 | 4 | 0.060 |
Why?
|
| Estradiol | 2 | 2017 | 262 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 767 | 0.060 |
Why?
|
| Japan | 1 | 2024 | 305 | 0.060 |
Why?
|
| Mice | 1 | 2013 | 5913 | 0.050 |
Why?
|
| Receptor, erbB-2 | 2 | 2014 | 133 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 66 | 0.050 |
Why?
|
| Adipokines | 1 | 2022 | 24 | 0.050 |
Why?
|
| Adiponectin | 1 | 2022 | 55 | 0.050 |
Why?
|
| Sleep | 1 | 2023 | 152 | 0.050 |
Why?
|
| Carnitine | 1 | 2021 | 8 | 0.050 |
Why?
|
| Sphingomyelins | 1 | 2021 | 11 | 0.050 |
Why?
|
| Glycine | 1 | 2021 | 47 | 0.050 |
Why?
|
| Serine | 1 | 2021 | 75 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2010 | 1908 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 81 | 0.050 |
Why?
|
| Microdissection | 1 | 2019 | 11 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 149 | 0.040 |
Why?
|
| Liver | 1 | 2021 | 479 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 77 | 0.040 |
Why?
|
| Testosterone Congeners | 1 | 2017 | 3 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 25 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 12 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 55 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 37 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 48 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2017 | 66 | 0.040 |
Why?
|
| North America | 1 | 2016 | 67 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 100 | 0.030 |
Why?
|
| Herpes Genitalis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Herpesvirus 2, Human | 1 | 2016 | 9 | 0.030 |
Why?
|
| Breast | 1 | 2017 | 135 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 41 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 321 | 0.030 |
Why?
|
| Intrauterine Devices | 1 | 2016 | 18 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 128 | 0.030 |
Why?
|
| Chlamydia trachomatis | 1 | 2016 | 68 | 0.030 |
Why?
|
| Lipids | 1 | 2017 | 235 | 0.030 |
Why?
|
| Term Birth | 1 | 2015 | 9 | 0.030 |
Why?
|
| Culture Media | 1 | 2015 | 90 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2015 | 50 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 113 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 353 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 72 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 127 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2015 | 101 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 623 | 0.030 |
Why?
|
| Gravidity | 1 | 2013 | 3 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 400 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 262 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2016 | 196 | 0.030 |
Why?
|
| Progesterone | 1 | 2013 | 113 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 602 | 0.030 |
Why?
|
| Mutation | 1 | 2017 | 1095 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 940 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 2011 | 6 | 0.030 |
Why?
|
| Peritoneum | 1 | 2011 | 8 | 0.030 |
Why?
|
| Integrin alpha5beta1 | 1 | 2011 | 5 | 0.030 |
Why?
|
| Talin | 1 | 2011 | 3 | 0.030 |
Why?
|
| Models, Biological | 1 | 2015 | 677 | 0.020 |
Why?
|
| Myosin Type II | 1 | 2011 | 18 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 336 | 0.020 |
Why?
|
| Fibronectins | 1 | 2011 | 66 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 212 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 502 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 41 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 143 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2008 | 151 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 409 | 0.020 |
Why?
|
| Population Dynamics | 1 | 2005 | 35 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 513 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 59 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 1354 | 0.020 |
Why?
|
| DNA | 1 | 2005 | 574 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1742 | 0.010 |
Why?
|